Eudragit-based nanosuspension of poorly water-soluble drug: Formulation and in vitro-in vivo evaluation

AAPS PharmSciTech

Volumn 13, Issue 4, 2012, Pages 1031-1044

  Yadav, Sarita Kumari ^a   Mishra, Shivani ^b   Mishra, Brahmeshwar ^a  

^a BANARAS HINDU UNIVERSITY   (India)

^b RAJ KUMAR GOEL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

diabetes mellitus; glimepiride; nanoprecipitation; poloxamer; sustained release

Indexed keywords

EUDRAGIT; GLIMEPIRIDE; GLUCOSE; NANOPARTICLE; NICOTINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG RELEASE; DRUG SOLUBILITY; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; NANOSUSPENSION; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ZETA POTENTIAL;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG STABILITY; FEMALE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; MALE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; POLYMETHACRYLIC ACIDS; RATS; SOLUBILITY; SULFONYLUREA COMPOUNDS; SUSPENSIONS; WATER;

EID: 84871669592     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9833-0     Document Type: Article

References (40)

1. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems. Int J Pharm. 2006;309(1-2):129-38.
2. Frick A, Moller H, Wirbitzki E. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Eur J Pharm Biopharm. 1998;46(3):305-11.
3. Ilic I, Dreu R, Burjak M, Homar M, Kerc J, Srcic S. Microparticle size control and glimepiride microencapsulation using spray congealing technology. Int J Pharm. 2009;381(2):176-83.
4. Babu RJ, Pandit JK. Effect of aging on the dissolution stability of glibenclamide/beta-cyclodextrin complex. Drug Dev Ind Pharm. 1999;25(11):1215-9.
5. Reven S, Grdadolnik J, Kristl J, Zagar E. Hyperbranched poly(esteramides) as solubility enhancers for poorly water-soluble drug glimepiride. Int J Pharm. 2010;396(1-2):119-26.
6. Junghanns JUAH, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309.
7. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59(7):631-44.
8. Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19(2):189-94.
9. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284(1-2):109-22.
10. Merisko-Liversidge EM, Liversidge GG. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol Pathol. 2008;36(1):43-8.
11. Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm. 2009;380(1-2):216-22.
12. Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm. 2002;237(1-2):151-61.
13. Reichal CR, Lakshmi JB, Ravi TK. Studies on formulation and in vitro evaluation of glimepiride floating tablets. J Chem Pharm Res. 2011;3(3):159-64.
14. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55(1):R1-4.
15. Guterres SS, Fessi H, Barratt G, Devissaguet JP, Puisieux F. Poly(dl-lactide) nanocapsules containing diclofenac: I. Formulation and stability study. Int J Pharm. 1995;113(1):57-63.
16. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev. 2006;58(15):1688-713.
17. Omari DM, Sallam A, Abd-Elbary A, El-Samaligy M. Lactic acid-induced modifications in films of Eudragit RL and RS aqueous dispersions. Int J Pharm. 2004;274(1-2):85-96.
18. Amlathe S, Gupta VK. Spectrophotometric determination of acetone using vanillin. Analyst. 1990;115(10):1385-7.
19. Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release. 2002;83(3):389-400.
20. Mishra B, Arya N, Tiwari S. Investigation of formulation variables affecting the properties of lamotrigine nanosuspension using fractional factorial design. Daru. 2010;18(1):1-8.
21. Rabbaa-Khabbaz L, Daoud RA, Karam-Sarkis D, Atallah C, Zoghbi A. A simple and sensitive method for determination of glimepiride in human serum by HPLC. J Liq Chromatogr Relat Technol. 2005;28(20):3255-63.
22. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, et al. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes. 1998;47(2):224-9.
23. Shirwaikar A, Rajendran K, Kumar CD, Bodla R. Antidiabetic activity of aqueous leaf extract of Annona squamosa in streptozotocin-nicotinamide type 2 diabetic rats. J Ethnopharmacol. 2004;91(1):171-5.
24. Lott JA, Turner K. Evaluation of Trinder's glucose oxidase method for measuring glucose in serum and urine. Clin Chem. 1975;21(12):1754-60.
25. Kuppusamy A, Muthusamy U, Thirumalaisamy SA, Varadharajan S, Ramasamy K, Ramanathan S. In vitro (α-glucosidase and α-amylase inhibition) and in vivo antidiabetic property of phytic Acid (IP6) in streptozotocin- nicotinamide-induced type 2 diabetes mellitus (NIDDM) in rats. J Complement Integr Med. 2011;8(1):doi:10.2202/1553-3840.1483.
26. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. Preparation and characterization of Eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech. 2006;7(1):E192-8. doi: 10.1208/pt070127.
27. Dillen K, Vandervoort J, Mooter GV, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles. Int J Pharm. 2006;314(1):72-82.
28. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(dl-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999;187(2):143-52.
29. Ubrich N, Schmidt C, Bodmeier R, Hoffman M, Maincent P. Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. Int J Pharm. 2005;288(1):169-75.
30. Bayems V, Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv. 1997;72(4):191-202.
31. Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine. 2010;6(2):318-23.
32. Thioune O, Fessi H, Devissaguet JP, Puisieux F. Preparation of pseudolatex by nanoprecipitation: influence of the solvent nature on intrinsic viscosity and interaction constant. Int J Pharm. 1997;146(2):233-8.
33. Passerini N, Albertini B, Gonzalez-Rodriguez ML, Cavallari C, Rodriguez L. Preparation and characterisation of ibuprofen-poloxamer 188 granules obtained by melt granulation. Eur J Pharm Sci. 2002;15(1):71-8.
34. Liu D, Fei X, Wang S, Jiang T, Su D. Increasing solubility and dissolution rate of drugs via eutectic mixtures: itraconazole-poloxamer188 system. Asian J Pharm Sci. 2006;1(3-4):213-21.
35. Glaessl B, Siepmann F, Tucker I, Siepmann J, Rades T. Characterisation of quaternary polymethacrylate films containing tartaric acid, metoprolol free base or metoprolol tartrate. Eur J Pharm Biopharm. 2009;73(3):366-72.
36. Dandagi P, Kerur S, Mastiholimath V, Gadad A, Kulkarni A. Polymeric ocular nanosuspension for controlled release of acyclovir: in vitro release and ocular distribution. IJPR. 2009;8(2):79-86.
37. Xie J, Wang CH. Self-assembled biodegradable nanoparticles developed by direct dialysis for the delivery of paclitaxel. Pharm Res. 2005;22(12):2079-90.
38. Kim YI, Fluckiger L, Hoffman M, Lartaud-Idjouadiene I, Atkinson J, Maincent P. The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. Br J Pharmacol. 1997;120(3):399-404.
39. Swanston-Flatt SK, Day C, Bailey CJ, Flatt PR. Traditional plant treatment for diabetes: studies in normal and streptozotocin diabetic mice. Diabetologia. 1990;33(8):462-4.
40. Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, Baccino FM, et al. Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med. 2008;44(4):584-93.